1.1800
01-十一月-24 14:59:56
15 分钟延时
股票
-0.0200
-1.67%
今日范围
1.1600 - 1.2185
ISIN
N/A
来源
NASDAQ
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
06 1月 2021 06:00:01 条件 Nasdaq GlobeNewswire